Loteprednol etabonate transmucosal - Kala Pharmaceuticals

Drug Profile

Loteprednol etabonate transmucosal - Kala Pharmaceuticals

Alternative Names: 0.25% LE-MPP; 1% LE-MPP; INVELTYS; KPI-121; KPI-121 0.25%; KPI-121 1%; LE-MPP; Loteprednol etabonate MPP; Loteprednol etabonate mucus-penetrating particles - Kala Pharmaceuticals; MPP-formulated loteprednol etabonate ophthalmic nanosuspension - Kala Pharmaceuticals

Latest Information Update: 15 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kala Pharmaceuticals
  • Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Eye disorder therapies; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Ocular inflammation; Ocular pain
  • Phase III Dry eyes
  • Phase II Diabetic macular oedema; Meibomianitis; Retinal vein occlusion

Most Recent Events

  • 19 Jun 2018 Kala Pharmaceuticals announces intention to submit NDA to US FDA for Dry eyes in second half of 2018
  • 19 Jun 2018 Kala Pharmaceuticals plans the phase III STRIDE 3 trial for KPI 121 0.25% in Dry eyes on recommendation by the US FDA
  • 09 May 2018 Kala Pharmaceuticals plans to launch INVELTYS™ for Ocular pain and Ocular inflammation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top